In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.

doi:10.1016/j.bmcl.2016.08.075

Paper

DOI: 10.1016/j.bmcl.2016.08.075

In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease.

Published Oct 1, 2016 · S. Banskota, Han-eol Kang, Dong-Guk Kim

Bioorganic & medicinal chemistry letters

Q2 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

6-amino-2,4,5-trimethylpyridin-3-ols show potential as a novel platform for anti-inflammatory bowel disease drug discovery, with compound 8m showing over 300-fold better efficacy than sulfasalazine in a rat model of colitis.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1111/bph.13476

Ozanimod (RPC1063) is a potent sphingosine‐1‐phosphate receptor‐1 (S1P1) and receptor‐5 (S1P5) agonist with autoimmune disease‐modifying activity

RPC1063 shows potential in treating autoimmune diseases by targeting S1P receptors and modulating immune responses.

2016·240citations·F. Scott et al.·British Journal of Pharmacology

British Journal of Pharmacology

DOI: 10.1016/j.pharmthera.2016.01.001

Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases.

TNF inhibitors' efficacy in inflammatory bowel disease is influenced by multiple mechanisms, leading to a more rational use and understanding of their mechanisms in vivo.

2016·87citations·C. Olesen et al.·Pharmacology & therapeutics

Pharmacology & therapeutics

DOI: 10.1371/journal.pone.0148133

BJ-1108, a 6-Amino-2,4,5-Trimethylpyridin-3-ol Analog, Inhibits Serotonin-Induced Angiogenesis and Tumor Growth through PI3K/NOX Pathway

BJ-1108 effectively inhibits serotonin-induced angiogenesis and tumor growth through the PI3K/NOX pathway, offering potential as a new antiangiogenic anticancer drug.

2016·32citations·S. Banskota et al.·PLoS ONE

PLoS ONE

DOI: 10.1155/2015/970890

Angiogenesis in Inflammatory Bowel Disease

Angiogenesis plays a crucial role in the pathogenesis of inflammatory bowel disease (IBD), supporting inflammation and wound healing, but potential treatments may have serious side effects due to their nature.

2015·121citations·C. Alkim et al.·International Journal of Inflammation

International Journal of Inflammation

DOI: 10.1016/j.coph.2015.11.007

Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

Anti-adhesion molecules show potential as a promising therapeutic option for active inflammatory bowel diseases, with Vedolizumab being approved for both Crohn's disease and ulcerative colitis.

2015·24citations·I. Bravatá et al.·Current opinion in pharmacology

Current opinion in pharmacology

Citations

DOI: 10.1021/acs.jmedchem.3c02458

G Protein-Coupled Estrogen Receptor-Mediated Anti-Inflammatory and Mucosal Healing Activity of a Trimethylpyridinol Analogue in Inflammatory Bowel Disease.

The GPER-selective compound 6-26 effectively reduces inflammation and restores colonic mucosal integrity in inflammatory bowel disease, showing potential as a therapeutic candidate.

2024·1citation·B. Awasthi et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

DOI: 10.3390/molecules27072075

Synthesis of Pyridoxine-Derived Dimethylpyridinols Fused with Aminooxazole, Aminoimidazole, and Aminopyrrole

This study successfully synthesized dimethylpyridinols from pyridoxine fused with aminooxazole and imidazole, but not with pyrrole, using a hydroxymethyl moiety at C(5)-position and an amino group at C(6)-position.

2022·0citations·B. Awasthi et al.·Molecules

Molecules

DOI: 10.1080/00397911.2021.2007403

Synthesis of a new functionalized pyridoxine derivatives based on 2-halopyridine-3,4-dicarbonitriles

Two new approaches for synthesizing functionalized pyridoxine derivatives with hydroxymethyl groups at positions 3 and 4 of the pyridine ring have been developed, enabling the synthesis of compounds with halogen atoms in the 2-position and 2-alkylamino-substituted

2021·1citation·S. V. Fedoseev et al.·Synthetic Communications

Synthetic Communications

DOI: 10.1016/j.bmcl.2021.128059

Synthesis and activity of N-(5-hydroxy-3,4,6-trimethylpyridin-2-yl)acetamide analogues as anticolitis agents via dual inhibition of TNF-α- and IL-6-induced cell adhesions.

Compound 2-19 shows potential as a dual-acting IBD drug, targeting both TNF- and IL-6 signaling, and shows better anticolitis activity than compound 1 and sulfasalazine.

2021·8citations·Ujjwala Karmacharya et al.·Bioorganic & medicinal chemistry letters

Bioorganic & medicinal chemistry letters

DOI: 10.1080/14756366.2021.1953997

Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol–sorafenib hybrids

Compound 6 shows potential as a promising hepatocellular carcinoma treatment with low toxic side effects on normal cells, offering a potential alternative to sorafenib.

2021·3citations·B. Awasthi et al.·Journal of Enzyme Inhibition and Medicinal Chemistry

Journal of Enzyme Inhibition and Medicinal Chemistry